Loading…
Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I
Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established...
Saved in:
| Published in: | International journal of nanomedicine 2022-01, Vol.17, p.635-646 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c542t-4dc702c8927f1e11fc125d7461c9889e88bf6faa2f2fa6c93bee19e25d5975bc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c542t-4dc702c8927f1e11fc125d7461c9889e88bf6faa2f2fa6c93bee19e25d5975bc3 |
| container_end_page | 646 |
| container_issue | |
| container_start_page | 635 |
| container_title | International journal of nanomedicine |
| container_volume | 17 |
| creator | Chen, Lu Zhou, Shan-Yong Zhu, Wei Liu, Sheng-Ping Zhang, Jing-Xi Zhuang, He Zhang, Jing-Ling Li, Yong-Sheng Gao, Fei |
| description | Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established point-of-care (POC) assays are insufficient to meet clinically analytical requirements due to their low sensitivity.
To this end, we established a highly sensitive and reliable POC lateral flow strip based on lanthanide-doped nanoparticles (NPs) for cTnI determination in human blood samples. The capture of cTnI on the lateral flow strip was performed in a sandwich assay, where Eu
-doped vanadate nanoparticles (GdVO
:30% Eu NPs) were used as luminescent probes to allow quantification.
Our platform realized the analytical sensitivity enhancement with limit-of-detection (LOD) as low as 17 pg mL
for cTnI detection, which was lower than the commercial counterpart; meanwhile, it displayed high specificity, excellent reproducibility and outstanding accuracy for analyzing clinical serum samples.
Overall, this strategy provided an ultrasensitive, cost-effective and user-friendly platform for on-site cTnI detection, demonstrating the prospect of lanthanide-doped NPs-based POC diagnosis of disease-related biomarkers. |
| doi_str_mv | 10.2147/IJN.S346415 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_03f2a978cd914875a9faaf51d130b1eb</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A696619466</galeid><doaj_id>oai_doaj_org_article_03f2a978cd914875a9faaf51d130b1eb</doaj_id><sourcerecordid>A696619466</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-4dc702c8927f1e11fc125d7461c9889e88bf6faa2f2fa6c93bee19e25d5975bc3</originalsourceid><addsrcrecordid>eNptkktvEzEURkcIREthxR6NxAYJTfBjxo8NUkkLCYoKUsva8niuE0cTe2pPKvXf1yGhNAh5Yevz8bHu1S2KtxhNCK75p_n3q8k1rVmNm2fFKcZcVARh-vzJ-aR4ldIaoYYLJl8WJ7TBnEtETws3c8tVf19eg09udHdQLrQfV9q7DqqLMEBXXmkfBh1HZ3pI1RedcvYzOD9WwVZTHaG8cHrpQ3KpDLacbTfalznvnDblTQxD8M6X89fFC6v7BG8O-1nx6-vlzXRWLX58m0_PF5VpajJWdWc4IkZIwi0GjK3BpOl4zbCRQkgQorXMak0ssZoZSVsALCEzjeRNa-hZMd97u6DXaohuo-O9Ctqp30GIS3UoRiFqiZZcmE7iWvBGyyy2De4wRS2GNrs-713Dtt1AZ8CPUfdH0uMb71ZqGe6UEDUViGbBh4MghtstpFFtXDLQ99pD2CZFGEUSSyR36Pt_0HXYRp9blSkiG0QZ4X-ppc4FOG9D_tfspOqcScawrBnL1OQ_VF4dbJwJHqzL-dGDj_sHJoaUItjHGjFSuylTecrUYcoy_e5pWx7ZP2NFHwCzGMvt</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2629503627</pqid></control><display><type>article</type><title>Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I</title><source>Publicly Available Content Database</source><source>Taylor & Francis Open Access(OpenAccess)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Chen, Lu ; Zhou, Shan-Yong ; Zhu, Wei ; Liu, Sheng-Ping ; Zhang, Jing-Xi ; Zhuang, He ; Zhang, Jing-Ling ; Li, Yong-Sheng ; Gao, Fei</creator><creatorcontrib>Chen, Lu ; Zhou, Shan-Yong ; Zhu, Wei ; Liu, Sheng-Ping ; Zhang, Jing-Xi ; Zhuang, He ; Zhang, Jing-Ling ; Li, Yong-Sheng ; Gao, Fei</creatorcontrib><description>Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established point-of-care (POC) assays are insufficient to meet clinically analytical requirements due to their low sensitivity.
To this end, we established a highly sensitive and reliable POC lateral flow strip based on lanthanide-doped nanoparticles (NPs) for cTnI determination in human blood samples. The capture of cTnI on the lateral flow strip was performed in a sandwich assay, where Eu
-doped vanadate nanoparticles (GdVO
:30% Eu NPs) were used as luminescent probes to allow quantification.
Our platform realized the analytical sensitivity enhancement with limit-of-detection (LOD) as low as 17 pg mL
for cTnI detection, which was lower than the commercial counterpart; meanwhile, it displayed high specificity, excellent reproducibility and outstanding accuracy for analyzing clinical serum samples.
Overall, this strategy provided an ultrasensitive, cost-effective and user-friendly platform for on-site cTnI detection, demonstrating the prospect of lanthanide-doped NPs-based POC diagnosis of disease-related biomarkers.</description><identifier>ISSN: 1178-2013</identifier><identifier>ISSN: 1176-9114</identifier><identifier>EISSN: 1178-2013</identifier><identifier>DOI: 10.2147/IJN.S346415</identifier><identifier>PMID: 35177903</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Antibodies ; Biomarkers ; cardiac troponin i ; Diagnosis ; gdvo4:30% eu nps ; Heart attack ; Heart attacks ; Humans ; Lanthanoid Series Elements ; lateral flow test strip ; Nanoparticles ; Original Research ; Point-of-Care Systems ; point-of-care test ; Prognosis ; Rare earth metals ; Reproducibility of Results ; Troponin I</subject><ispartof>International journal of nanomedicine, 2022-01, Vol.17, p.635-646</ispartof><rights>2022 Chen et al.</rights><rights>COPYRIGHT 2022 Dove Medical Press Limited</rights><rights>2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Chen et al. 2022 Chen et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-4dc702c8927f1e11fc125d7461c9889e88bf6faa2f2fa6c93bee19e25d5975bc3</citedby><cites>FETCH-LOGICAL-c542t-4dc702c8927f1e11fc125d7461c9889e88bf6faa2f2fa6c93bee19e25d5975bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2629503627/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2629503627?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35177903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Lu</creatorcontrib><creatorcontrib>Zhou, Shan-Yong</creatorcontrib><creatorcontrib>Zhu, Wei</creatorcontrib><creatorcontrib>Liu, Sheng-Ping</creatorcontrib><creatorcontrib>Zhang, Jing-Xi</creatorcontrib><creatorcontrib>Zhuang, He</creatorcontrib><creatorcontrib>Zhang, Jing-Ling</creatorcontrib><creatorcontrib>Li, Yong-Sheng</creatorcontrib><creatorcontrib>Gao, Fei</creatorcontrib><title>Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I</title><title>International journal of nanomedicine</title><addtitle>Int J Nanomedicine</addtitle><description>Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established point-of-care (POC) assays are insufficient to meet clinically analytical requirements due to their low sensitivity.
To this end, we established a highly sensitive and reliable POC lateral flow strip based on lanthanide-doped nanoparticles (NPs) for cTnI determination in human blood samples. The capture of cTnI on the lateral flow strip was performed in a sandwich assay, where Eu
-doped vanadate nanoparticles (GdVO
:30% Eu NPs) were used as luminescent probes to allow quantification.
Our platform realized the analytical sensitivity enhancement with limit-of-detection (LOD) as low as 17 pg mL
for cTnI detection, which was lower than the commercial counterpart; meanwhile, it displayed high specificity, excellent reproducibility and outstanding accuracy for analyzing clinical serum samples.
Overall, this strategy provided an ultrasensitive, cost-effective and user-friendly platform for on-site cTnI detection, demonstrating the prospect of lanthanide-doped NPs-based POC diagnosis of disease-related biomarkers.</description><subject>Antibodies</subject><subject>Biomarkers</subject><subject>cardiac troponin i</subject><subject>Diagnosis</subject><subject>gdvo4:30% eu nps</subject><subject>Heart attack</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Lanthanoid Series Elements</subject><subject>lateral flow test strip</subject><subject>Nanoparticles</subject><subject>Original Research</subject><subject>Point-of-Care Systems</subject><subject>point-of-care test</subject><subject>Prognosis</subject><subject>Rare earth metals</subject><subject>Reproducibility of Results</subject><subject>Troponin I</subject><issn>1178-2013</issn><issn>1176-9114</issn><issn>1178-2013</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNptkktvEzEURkcIREthxR6NxAYJTfBjxo8NUkkLCYoKUsva8niuE0cTe2pPKvXf1yGhNAh5Yevz8bHu1S2KtxhNCK75p_n3q8k1rVmNm2fFKcZcVARh-vzJ-aR4ldIaoYYLJl8WJ7TBnEtETws3c8tVf19eg09udHdQLrQfV9q7DqqLMEBXXmkfBh1HZ3pI1RedcvYzOD9WwVZTHaG8cHrpQ3KpDLacbTfalznvnDblTQxD8M6X89fFC6v7BG8O-1nx6-vlzXRWLX58m0_PF5VpajJWdWc4IkZIwi0GjK3BpOl4zbCRQkgQorXMak0ssZoZSVsALCEzjeRNa-hZMd97u6DXaohuo-O9Ctqp30GIS3UoRiFqiZZcmE7iWvBGyyy2De4wRS2GNrs-713Dtt1AZ8CPUfdH0uMb71ZqGe6UEDUViGbBh4MghtstpFFtXDLQ99pD2CZFGEUSSyR36Pt_0HXYRp9blSkiG0QZ4X-ppc4FOG9D_tfspOqcScawrBnL1OQ_VF4dbJwJHqzL-dGDj_sHJoaUItjHGjFSuylTecrUYcoy_e5pWx7ZP2NFHwCzGMvt</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Chen, Lu</creator><creator>Zhou, Shan-Yong</creator><creator>Zhu, Wei</creator><creator>Liu, Sheng-Ping</creator><creator>Zhang, Jing-Xi</creator><creator>Zhuang, He</creator><creator>Zhang, Jing-Ling</creator><creator>Li, Yong-Sheng</creator><creator>Gao, Fei</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I</title><author>Chen, Lu ; Zhou, Shan-Yong ; Zhu, Wei ; Liu, Sheng-Ping ; Zhang, Jing-Xi ; Zhuang, He ; Zhang, Jing-Ling ; Li, Yong-Sheng ; Gao, Fei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-4dc702c8927f1e11fc125d7461c9889e88bf6faa2f2fa6c93bee19e25d5975bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Biomarkers</topic><topic>cardiac troponin i</topic><topic>Diagnosis</topic><topic>gdvo4:30% eu nps</topic><topic>Heart attack</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Lanthanoid Series Elements</topic><topic>lateral flow test strip</topic><topic>Nanoparticles</topic><topic>Original Research</topic><topic>Point-of-Care Systems</topic><topic>point-of-care test</topic><topic>Prognosis</topic><topic>Rare earth metals</topic><topic>Reproducibility of Results</topic><topic>Troponin I</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Lu</creatorcontrib><creatorcontrib>Zhou, Shan-Yong</creatorcontrib><creatorcontrib>Zhu, Wei</creatorcontrib><creatorcontrib>Liu, Sheng-Ping</creatorcontrib><creatorcontrib>Zhang, Jing-Xi</creatorcontrib><creatorcontrib>Zhuang, He</creatorcontrib><creatorcontrib>Zhang, Jing-Ling</creatorcontrib><creatorcontrib>Li, Yong-Sheng</creatorcontrib><creatorcontrib>Gao, Fei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Lu</au><au>Zhou, Shan-Yong</au><au>Zhu, Wei</au><au>Liu, Sheng-Ping</au><au>Zhang, Jing-Xi</au><au>Zhuang, He</au><au>Zhang, Jing-Ling</au><au>Li, Yong-Sheng</au><au>Gao, Fei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I</atitle><jtitle>International journal of nanomedicine</jtitle><addtitle>Int J Nanomedicine</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>17</volume><spage>635</spage><epage>646</epage><pages>635-646</pages><issn>1178-2013</issn><issn>1176-9114</issn><eissn>1178-2013</eissn><abstract>Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established point-of-care (POC) assays are insufficient to meet clinically analytical requirements due to their low sensitivity.
To this end, we established a highly sensitive and reliable POC lateral flow strip based on lanthanide-doped nanoparticles (NPs) for cTnI determination in human blood samples. The capture of cTnI on the lateral flow strip was performed in a sandwich assay, where Eu
-doped vanadate nanoparticles (GdVO
:30% Eu NPs) were used as luminescent probes to allow quantification.
Our platform realized the analytical sensitivity enhancement with limit-of-detection (LOD) as low as 17 pg mL
for cTnI detection, which was lower than the commercial counterpart; meanwhile, it displayed high specificity, excellent reproducibility and outstanding accuracy for analyzing clinical serum samples.
Overall, this strategy provided an ultrasensitive, cost-effective and user-friendly platform for on-site cTnI detection, demonstrating the prospect of lanthanide-doped NPs-based POC diagnosis of disease-related biomarkers.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>35177903</pmid><doi>10.2147/IJN.S346415</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-2013 |
| ispartof | International journal of nanomedicine, 2022-01, Vol.17, p.635-646 |
| issn | 1178-2013 1176-9114 1178-2013 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_03f2a978cd914875a9faaf51d130b1eb |
| source | Publicly Available Content Database; Taylor & Francis Open Access(OpenAccess); PubMed Central; Coronavirus Research Database |
| subjects | Antibodies Biomarkers cardiac troponin i Diagnosis gdvo4:30% eu nps Heart attack Heart attacks Humans Lanthanoid Series Elements lateral flow test strip Nanoparticles Original Research Point-of-Care Systems point-of-care test Prognosis Rare earth metals Reproducibility of Results Troponin I |
| title | Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T00%3A27%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highly%20Sensitive%20Lanthanide-Doped%20Nanoparticles-Based%20Point-of-Care%20Diagnosis%20of%20Human%20Cardiac%20Troponin%20I&rft.jtitle=International%20journal%20of%20nanomedicine&rft.au=Chen,%20Lu&rft.date=2022-01-01&rft.volume=17&rft.spage=635&rft.epage=646&rft.pages=635-646&rft.issn=1178-2013&rft.eissn=1178-2013&rft_id=info:doi/10.2147/IJN.S346415&rft_dat=%3Cgale_doaj_%3EA696619466%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c542t-4dc702c8927f1e11fc125d7461c9889e88bf6faa2f2fa6c93bee19e25d5975bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2629503627&rft_id=info:pmid/35177903&rft_galeid=A696619466&rfr_iscdi=true |